About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Why Donít the Alzheimer Drugs Work on Patients?

by Rishika Gupta on October 27, 2017 at 5:41 PM
Font : A-A+

Why Donít the Alzheimer Drugs Work on Patients?

Semagacestat may not be true γ-secretase inhibitors as largely assumed, but alternatively, they may result in accumulation of toxic intraneuronal Aβ, found a new study published in Cell Report journal.

By reducing Aβ production,γ-secretase inhibitors were considered able to treat Alzheimer's disease (Aβ hypothesis). In fact, nearly 50 clinical trials have been conducted using potential γ-secretase inhibitors for Alzheimer's disease or several types of cancer. However, all of these trials have failed, except for two studies, which are currently ongoing.

Advertisement


Osaka University scientists found that some potential γ-secretase inhibitors such as semagacestat, which were used in large clinical trials failed because they did not function as true inhibitors as originally expected, but rather caused a significant accumulation of toxic intraneuronal Aβ peptide.

They proved this by introducing an original method to measure direct intracellular products of γ-secretase. They commented that the application of their evaluation method might help develop truly effective drugs for Alzheimer's disease (AD).
Advertisement

The study can be seen in Cell Reports and provides an explanation for why the clinical trials for Alzheimer's disease drugs have failed and gives new light on the discord between preclinical and clinical findings.

"Aβ accumulates in the brain at the very early stages of Alzheimer's disease," explains Osaka University Associate Professor Masayasu Okochi, an expert on the disease who managed the project.

"Aβ generation is based on the activity of presenilin/γ-secretase which mediates the cellular production of Aβ."

Of the promising sets of drugs for Alzheimer's disease were γ-secretase inhibitors like semagacestat. However, a clinical trial that began almost ten years ago was terminated early because not only was semagacestat found to fail, patient groups that received the drug showed exasperated symptoms compared to the placebo group. This finding has put great doubt into the Aβ hypothesis.

To understand this surprising finding, Okochi considered whether semagacestat is indeed a γ-secretase inhibitor. In this study, he and colleagues revealed that semagacestat does not really inhibit the target function, i.e., the cleavage performed by γ-secretase (γ-cleavage).

What enabled them to reach this unexpected finding is an original method that this team established, which can measure direct products of γ-secretase (peptides of 3 to 5 small amino-acid residues which were named γ-byproducts).

Surprisingly, non-transition state analog γ-secretase inhibitors including semagacestat did not decrease but rather increased the levels of γ-by-products.

This finding shattered the belief that these compounds truly inhibit the proteolytic function of γ-secretase and made the researchers "look" inside neurons for further assessment.

As predicted from the increased level of γ-byproducts, an accumulation of Aβ was found inside neurons derived from human iPS cells and various types of cultured cells, although semagacestat did in fact decrease secreted Aβ, as has been previously reported.

These results suggested to Okochi that semagacestat is not, in fact, a γ-secretase inhibitor, which is why he uses the term "pseudo γ-secretase inhibitor" in the study.

Clinical tests of semagacestat tended to judge the drug based on Aβ secretion but not γ-byproducts, which could explain why pseudo γ-secretase inhibitors have repeatedly been mislabeled.

"We found the type of assay gives different results. In our assay, we found γ-byproducts in the cell membrane. Semagacestat may prevent the release of γ-byproducts from the membrane but not the generation of γ-byproducts," he said.

Ironically, notes Okochi, considering his findings, he argues the failed clinical trials affirm the Aβ hypothesis.

"I believe normalization of production and secretion of Aβ by sharpening γ-secretase is the right approach to treating Alzheimer's disease. Our tests suggest that molecularly targeted therapy should be thoroughly checked from all angles before its application to clinical studies.

The new function of γ-secretase suggested in this study needs further analysis, which will contribute to the development of truly effective drugs for Alzheimer's disease and several types of cancer," he said.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Turmeric: Magic Ingredient to Keep you Healthy in Winter
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Alzheimers Disease Drug Toxicity Drugs Banned in India Creutzfeldt-Jakob Disease Diet and Alzheimerīs Disease Genetics of Alzheimerīs disease 

Recommended Reading
Alzheimers Disease
Alzheimer's disease is a progressive neurodegenerative disease affecting memory and thinking and ......
Quiz On Alzheimerís Disease
Alzheimer's disease (AD) is the most common form of dementia. Participate in this quiz to find out ....
New Genetic Connections of Alzheimer's Disease Identified
A genetic variant linked to the accumulation of neurofibrillary tangles (NFT) inside the neuron in ....
New Hope For Early Detection And Monitoring Of Alzheimer's Disease
A noninvasive eye scan helps in detecting key signs of Alzheimer's disease years before patients ......
Creutzfeldt-Jakob Disease
Creutzfeldt-Jakob disease (CJD) is a rare form of degenerative brain disorder, or brain damage that ...
Diet and Alzheimerīs Disease
Alzheimer''s begins with forgetfulness, but over time affects speech and coordination along with dra...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Genetics of Alzheimerīs disease
There are numerous genes that have been discovered that are associated with Alzheimerís disease and ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use